B-Cell Chronic Lymphocytic Leukemia
- Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline.
The report provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia
(CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Durable treatment-free remission and effective retreatment in patients with relapsed/refractory chronic lymphocytic leukemia
who achieved a deep response with venetoclax combined with rituximab; Brander et al.
Biopharmaceutical company AbbVie (NYSE:ABBV) reported on Friday that it has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for the use of IMBRUVICA (ibrutinib) plus bendamustine and rituximab (BR) versus placebo plus BR in relapsed or refractory patients with chronic lymphocytic leukemia
(CLL) or small lymphocytic lymphoma (SLL).
This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia
(CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia
patients with 13q14 deletion.
Chronic lymphocytic leukemia
(CLL) is one of the most common lymphoid malignancies, accounting for more than 10% of all lymphoid neoplasms, and is the most common adult leukemia in Western countries, with an age-adjusted annual incidence rate of about 4 cases per 100.
Histologic examination showed expansion of the red pulp and effacement of the white pulp by chronic lymphocytic leukemia
and, in addition, several abscesses containing brightly eosinophilic crystalline structures in the "starburst" pattern of Splendore-Hoeppli material (Figure, A and B).
He adds that the drug may also impede other cancers, such as B cell lymphoma and chronic lymphocytic leukemia
com/research/xsk3w5/relapsed) has announced the addition of Global Markets Direct's new report "Relapsed/ Refractory Chronic Lymphocytic Leukemia
(CLL) - Pipeline Review, H2 2012" to their offering.